Sub-acute toxicity studies on a new piperidine derivative (HSR-902) in dogs.
The administration of a new piperidine antispasmodic agent (HSR-902) to the dog by the oral and intravenous routes, induced clinical signs attributable to parasympathetic blockage. The only significant toxicological finding was rarefied appearance and enlargement of the hepatocytes at the high dose level (50 mg/kg/day); this was shown to be reversible.
D000284:Administration, Oral; D000818:Animals; D001772:Blood Cell Count; D001835:Body Weight / Q000187:drug effects; D004285:Dogs; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D007275:Injections, Intravenous; D008297:Male; D010276:Parasympatholytics / Q000008:administration & dosage / Q000633:toxicity*; D011807:Quinolizines / Q000008:administration & dosage / Q000633:toxicity*
D010276:Parasympatholytics; D011807:Quinolizines; C030950:thiaton